Much Ado about ASPS: The Rapidly Changing Treatment Paradigms of 2022.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36692840.
- Also identified by DOI 10.1158/1078-0432.CCR-22-3399.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A recent randomized phase II study of sunitinib or cediranib in alveolar soft part sarcoma established benchmark activity for commonly used tyrosine kinase inhibitors (TKI). The impact of TKIs, as well as immunotherapy, has redefined treatment paradigms and greatly improved outcomes for this historically dismal sarcoma. See related article by Nguyen et al., p. 1200.
Medical subject headings
- Sarcoma, Alveolar Soft Part
- Antineoplastic Agents